

## PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR $\gamma$ /PRO12ALA POLYMORPHISM AND PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR $\gamma$ COACTIVATOR-1 ALPHA/GLY482SER POLYMORPHISM IN PATIENTS WITH SARCOIDOSIS

A. Maver<sup>1</sup>, I. Medica<sup>1</sup>, B. Salobir<sup>2</sup>, M. Tercej-Zorman<sup>2</sup>, M. Sabovic<sup>2</sup>, D. Petrovic<sup>3</sup>, B. Peterlin<sup>1</sup>

<sup>1</sup>Division of Medical Genetics, Department of Gynecology and Obstetrics, University Clinical Centre;

<sup>2</sup>Department of Pulmonary Diseases and Allergy, University Clinical Centre; <sup>3</sup>Institute of Histology and Embryology, Medical Faculty, Ljubljana, Slovenia

**ABSTRACT.** *Background and aim of the work:* Reduced expression and activity of the peroxisome proliferator-activated receptor  $\gamma$  (PPARG) have been measured in cells of bronchoalveolar lavage fluid in sarcoidosis patients. PPARG, together with its transcriptional coactivator peroxisome proliferator-activated receptor  $\gamma$  coactivator-1 alpha (PPARGC1A), has important modulating effects on immune response and apoptosis. In the present study, we investigated whether the polymorphisms Pro12Ala (rs1805192) in the PPARG gene and Gly482Ser (rs8192678) in the PPARGC1A gene, which affect transcriptional activities, are associated with sarcoidosis. *Methods:* We performed an integrative "omic" approach and identified the PPARG gene as a suitable candidate. Polymerase chain reaction was performed followed by restriction fragment length polymorphism to determine PPARG/Pro12Ala and PPARGC1A/Gly482Ser genotypes of 104 sarcoidosis patients and 112 healthy control subjects. *Results:* A higher frequency of the Ala allele ( $p=0.0101$ , OR=1.84, CI 1.18-2.88), as well as a significantly higher frequency of Pro/Ala heterozygotes and Ala/Ala homozygotes at the Pro12Ala/PPARG polymorphism ( $p=0.0020$ , OR=2.45, CI 1.42-4.25) were found in patients with sarcoidosis. In addition, a higher frequency of the Ser allele ( $p=0.013$ , OR=1.69, CI 1.13-2.53) and Gly/Ser heterozygotes and Ser/Ser homozygotes ( $p=0.0470$ , OR=1.80, CI 1.04-3.10) at the Gly482Ser/PPARGC1A polymorphism were found in patients with sarcoidosis as compared to healthy control subjects. *Conclusion:* Our results indicate that the presence of the Ala allele at the PPARG/Pro12Ala polymorphism and the Ser allele at the PPARGC1A/Gly482Ser polymorphism may be a predisposing factor for sarcoidosis. (*Sarcoidosis Vasc Diffuse Lung Dis* 2008; 25: 29-35)

**KEY WORDS:** sarcoidosis, peroxisome proliferator-activated receptor  $\gamma$ , Pro12Ala polymorphism, peroxisome proliferator-activated receptor  $\gamma$  coactivator-1 alpha, Gly482Ser polymorphism, association study, integrative "omic" approach

### INTRODUCTION

Sarcoidosis is a multi-system chronic inflammatory disorder of unknown cause characterized by multiple granulomas consisting of epithelioid macrophage cells and T-lymphocytes, resulting from a Th1 type immunological response to an unknown antigen.

Received: 9 September 2006

Accepted after Revision: 08 July 2008

Correspondence: Borut Peterlin, MD, PhD

Division of Medical Genetics, Department of Gynecology and Obstetrics, University Clinical Centre Ljubljana, Slovenia  
3, Slajmerjeva str, Ljubljana 1000, Slovenia

Tel/fax: +386 (0) 1 5401137

E mail: borut.peterlin@guest.arnes.si

As the role of infectious agents has not been confirmed (1, 2) a genetic influence has been proposed. Familial clustering of the disease (3-5), differences in disease prevalence and disease severity among ethnic groups and association with the HLA locus on chromosome 6 (6) all speak in favor of its heritability. A complex inheritance model has been proposed and a number of association studies have been performed with the aim of identifying candidate genes (6, 7).

A literature search of genes coding for proteins potentially involved in the pathophysiology of sarcoidosis was accomplished using a literature-based biomedical discovery algorithm BITOLA (8) and a web-based literature database PubMed MEDLINE. After searching for potential gene candidates using PubMed, BITOLA was used to examine which gene candidates are involved in pathologic processes that result in sarcoidosis, but have not yet been related to sarcoidosis in previous studies and therefore signify a new discovery. To narrow the selection of candidates, the data from several transcriptomic (9-14) and proteomic studies (9, 13, 15-18) were considered.

Additionally, genomic position in the proximity of peaks of LOD score, which was previously determined in a nonparametric multipoint linkage analysis in German families with affected siblings (19), was considered.

A set of candidate genes was identified and investigated: seven of them are involved in immunologic processes, five affect the redox state of cells, three regulate cell proliferation and apoptosis, three influence calcium metabolism, two affect cell adhesion properties and one is involved in fibrinolytic pathways. The PPARG gene was selected as a suitable candidate based on the results of the study by Culver et al. which demonstrated reduced gene expression and protein production and thus deficient PPARG activity (9).

The PPARG gene lies in the proximity of the D3S1259 polymorphism, which shows a slightly increased LOD score (19). Previously recognized polymorphisms affecting the transcriptional activity of PPARG and PPARGC1A, Pro12Ala and Gly482Ser respectively, were selected to investigate our assumption, by means of an association study (20, 21).

The protein peroxisome proliferator-activated receptor  $\gamma$  (PPARG) is a ligand-activated transcription factor with modulating effects on immune re-

sponse. Its anti-inflammatory effect is due to inactivation of the proinflammatory transcription factors NF- $\kappa$ B, activator protein (AP)-1 and STAT1 (22-28). A polymorphism in exon B causing the substitution of proline with alanine at amino acid position 12 (Pro12Ala, rs1805192) has been described, with consequent decreased PPARG function (20). The gene expression is significantly lower in alveolar macrophages from sarcoid lungs (9). It has also been demonstrated that production of tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ), interleukin-6 (IL-6) and other cytokines which are overproduced in sarcoidosis, is influenced by PPARG (28). Peroxisome proliferator-activated receptor  $\gamma$  coactivator-1 $\alpha$  (PPARGC1A) is a transcriptional coactivator that increases the transcriptional activity of PPARG (29). A polymorphism that causes substitution of glycine with serine at position 482 (Gly482Ser, rs8192678) of the protein has been described in its coding region (21) and reported to affect its function (30).

In order to evaluate a possible involvement of PPARG and PPARGC1A in the etiology of sarcoidosis, we performed an association study of the PPARG/Pro12Ala and PPARGC1/Gly482Ser polymorphisms in Slovenian patients with sarcoidosis.

## PATIENTS AND METHODS

### *Patients*

Subjects diagnosed with sarcoidosis were recruited from an ongoing sarcoidosis registry begun in 2000 at the University Clinical Centre Ljubljana, Department of Pulmonary and Allergic Diseases. The diagnosis of sarcoidosis was made based on the clinical picture, radiographic presentation, bronchoalveolar lavage (BAL) and biopsy specimen from the lung, skin or lymph nodes after other granulomatous diseases were excluded. One hundred and four patients were included in the study: 36 males and 68 females, age range 21-68 years, mean age 41 years. The patients were followed from 3 to 10 years after confirmation of diagnosis. Regarding the clinical presentation at diagnosis, pulmonary lymph nodes were affected in 89 and lung interstitium in 73 patients. According to the classification system (31), 15 patients were in stage I, 55 in stage II, 16 in stage

III and 2 in stage IV at the time of the first visit. Extra-pulmonary organ involvement was found in 35 patients. Various types of skin involvement were found in 31 patients and Löfgren's syndrome was present in 19 patients. Eight patients had arthralgias. Ten patients had extrapulmonary lymph node involvement. Five patients had salivary gland involvement. In 15 patients, parenchymal organs such as liver, spleen, kidney or heart were involved and in 9 patients, various types of neural involvement were present. Regarding the clinical course, 47 patients had active disease after two years of follow up and were thus diagnosed with chronic sarcoidosis, while 57 patients who recovered within two years after diagnosis were diagnosed as acute form.

The control group consisted of 112 healthy, randomly chosen blood donors: 66 males and 46 females, age range between 39 and 65 years, mean age 52 years.

All patient and control subjects were Slovenians, unrelated to one another. All subjects participated in the study after they had given their full informed consent. The study was approved by the National Ethics Committee.

#### *Molecular analysis*

After DNA isolation from blood leukocytes by standard procedure, polymerase chain reaction (PCR) method was performed to detect the Pro12Ala polymorphism of the PPARG gene and the Gly482Ser polymorphism of the PPARGC1A gene.

For the Pro12Ala/PPARG analysis, the sequences of primers were: forward (P12A-F) 5'-CAAGCCCAGTCCTTTCTGTG-3'; reverse (P12A-R) 5'-AGCTATGACCAGTGAAGGAA-TCGCTTTCCG-3'.

PCR amplification was performed on 500 ng of DNA in a 10 µl reaction mix containing: 1 µl of 10 x standard PCR buffer, 0.2 mM of each dNTP, 2.5 mM MgCl<sub>2</sub>, 10 picomoles of each primer and 1 unit of Taq DNA polymerase (Promega, Madison, WI). The protocol of PCR amplification was as follows: initial denaturation at 94°C for 10 min, followed by 29 cycles at 94°C for 60 sec, 58°C for 90 sec and 72°C for 60 sec. and a final extension at 72°C for 10 min (Whatman Biometra Tgradient Thermocycler 2400, Germany).

After the amplification, the 237 bp large PCR products were digested with 5 units of MspI restriction enzyme (Promega, Madison, WI) at 37°C overnight and run on 2% agarose gel with ethidium bromide. The enzyme cuts the restriction site if the Pro allele is present resulting in 2 bands of 217 and 20 bp.

The Gly48Ser/PPARGC1A polymorphism analysis was performed using a forward primer (G48S-F) 5'-TAAAGATGTCTCCTCTGATT-3' and a reverse primer (G48S-R) 5'-GGAGACA-CATTGAACAATGAATAGGATTG-3'.

The PCR was carried out on 500 ng of DNA in a total reaction volume of 10 µl containing 1 x PCR buffer, 0.2 mM dNTPs, 2.5 mM MgCl<sub>2</sub>, 1 picomole of each primer, 1 unit of Taq polymerase. The protocol of PCR amplification was as follows: initial denaturation at 95°C for 10 min, followed by 40 cycles at 95°C for 30 sec, 58°C for 30 sec and at 72°C for 60 sec, with the final extension at 72°C for 10 min.

After the amplification, the 378 bp large PCR products were digested with 5U of MspI restriction enzyme at 37°C overnight) and visualized in 2% agarose gel with ethidium bromide. The enzyme cuts the restriction site if the Gly allele is present resulting in 2 bands of 207 and 171 bp.

#### *Statistical analyses*

The statistical analysis was performed by SPSS for Windows 13.0 and MedCalc 8.2 software. The Chi-Square test was used for analysis of statistical significance, where a probability (p) value of less than 0.05 was considered statistically significant and the odds ratio (OR) value was used to compare allelic and genotype distribution in patients and control subjects. Additionally, the same tests were carried out to compare genotype distributions between the acute and the chronic patient groups. Statistical power of the two analyses was also calculated.

The calculation of statistical power of the test revealed that in both analyses, the sample size of 104 patients and 112 control subjects, would result in 80% probability to detect a 2-fold increase in the frequency of risk genotypes, assuming the percentage of risk genotype in PPARG polymorphism analysis in control subjects to be 34.8%, and the percentage of risk genotype in PPARGC1A analysis in control subjects to be 49.1% (p < 0.05).

## RESULTS

### Results of gene candidates search

#### Results of PPARG and PPARGC1A genotyping

The results of the genotyping in patients with sarcoidosis and in healthy controls for the PPARG/Pro12Ala and PPARGC1A/Gly482Ser polymorphisms are summarized in tables 1 and 2.

An increased frequency of the Ala allele at the PPARG/Pro12Ala polymorphism site ( $p=0.0101$  and  $OR=1.84$ ,  $CI$  1.18-2.88) was found in patients with sarcoidosis as compared to control subjects. In addition, an increased frequency of the Pro/Ala heterozygous plus the Ala/Ala homozygous genotypes ( $p=0.0020$ ,  $OR=2.45$ ,  $CI$  1.42-4.25) as opposed to the Pro/Pro homozygote genotype was found in patients with sarcoidosis. When comparing Ala/Ala and Pro/Pro genotype frequencies, between sarcoidosis patients and healthy controls, an increased frequency, although not statistically significant, of Ala/Ala homozygotes was detected in the patient group ( $p^21$ ,  $p=1?$ ,  $OR=1.62$ ,  $CI$  0.31-

8.38). A statistically significant increased frequency of Pro/Ala heterozygotes was also found, compared to Pro/Pro homozygotes ( $p^20.01$ ,  $OR=2.52$ ,  $CI$  1.44-4.41).

Regarding the PPARGC1A/Gly482Ser polymorphism analysis, an increase in frequency of Ser allele in the sarcoidosis patients was found as compared to the control subjects ( $p=0.013$ ,  $OR=1.69$ ,  $CI$  1.13-2.53).

In the patient group, there was a higher frequency of the Gly/Ser heterozygous plus Ser/Ser homozygous genotypes ( $p=0.0470$ ,  $OR=1.80$ ,  $CI$  1.04-3.10) as opposed to the Gly/Gly homozygous genotype. A statistically significant increased frequency of homozygotes was detected in the sarcoidosis patients group as compared to controls  $p<0.025$ ,  $OR=3.18$ ,  $CI$  1.25-8.12). In the patient group, a increased frequency, although not statistically significant of Gly/Ser heterozygotes comparing to the wild type homozygote was found ( $p<0.20$ ,  $OR=1.49$ ,  $CI$  0.88-2.77).

When comparing the genotype distributions within the sarcoidosis group patients, for both analy-

**Table 1.** Allele and genotype frequencies of PPARG/Pro12Ala polymorphism in patients with sarcoidosis and in control subjects.

Allele/Genotype	Sarcoidosis n (%)	m	f	Controls n (%)	m	f	OR (95% CI)	P
Allele								
Pro	146 (70.2)			182 (81.2)			1.84 (1.18 to 2.,88)	0.01
Ala	62 (29.8)			42 (18.8)				
Total	208 (100)			224 (100)				
Genotype							Ala/Ala+Pro/Ala vs. Pro/Pro 2.45 (1.42 to 4.25)	0.002
Pro/Pro	45 (43.2)	31	14	73 (65.2)	35	38		
Pro/Ala	56 (53.9)	35	21	36 (32.1)	11	25		
Ala/Ala	3 (2.9)	2	1	3 (2.7)	0	3		
Total	104 (100)	68	36	112 (100)	46	66		

f=female, m=male

**Table 2.** Allele and genotype frequencies of PPARGC1A/Gly482Ser polymorphism in patients with sarcoidosis and in control subjects.

Allele/Genotype	Sarcoidosis n (%)	m	f	Controls n (%)	m	f	OR (95% CI)	P
Allele:								
Gly	125 (60.1)			161 (71.9)			1.69 (1.13 to 2.53)	0.013
Ser	83 (39.9)			63 (28.1)				
Total	208 (100)			224 (100)				
Genotype							Ser/Ser+Gly/Ser vs. Gly/Gly 1.80 (1.04 to 3.10)	0.0470
Gly/Gly	38 (36.5)	26	12	57 (50.9)	21	23		
Gly/Ser	49 (47.1)	34	15	47 (42.0)	22	35		
Ser/Ser	17 (16.4)	8	9	8 (7.1)	3	8		
Total	104 (100)	68	36	112 (100)	46	66		

f=female, m=male

ses, there were no statistically significant differences between acute and chronic groups of sarcoidosis patients (data not shown).

Additionally, in order to evaluate a possible gene-gene interaction between PPARG and PPARGC1A, the correlation between the disease and the combination of the risk genotypes at both polymorphisms was examined in every sarcoidosis patient and control subject. No significant correlation was found between the combined risk genotypes and the disease (data not shown). There was no statistically significant deviation from Hardy-Weinberg equilibrium in both analyses ( $p < 0.05$ ).

## DISCUSSION

Our study demonstrated a higher frequency of the Ala polymorphism of the PPARG gene and the Ser polymorphism of the PPARGC1A gene in sarcoidosis patients. The involvement of PPARG in the pathogenesis of sarcoidosis can be postulated on the basis of previously reported expression, proteomic and function studies.

Culver et al. (9) demonstrated that BAL specimens from patients with sarcoidosis revealed a striking reduction of PPARG activity in alveolar macrophages on the electrophoretic mobility shift assay, a decrease in PPARG nuclear protein and gene expression with immunostaining and real-time polymerase chain reaction, greatly reduced promoter binding affinity and reduced mRNA expression of PPARG as compared to healthy control subjects.

In addition, two major lines of evidence that support the role of PPARG pathway in sarcoidosis are its role in inflammatory/immune response regulation (22, 23, 27, 28, 32) and in apoptotic processes (33-35).

Increased gene expression or production of TNF- $\alpha$ , IL-6, inducible nitric oxid synthase, interferon- $\gamma$  and matrix metalloproteinases has also been demonstrated (23, 10, 36-42). These mediators are encoded by genes normally under transcriptional inhibition of PPARG (28, 43, 44).

Enhanced activity of the transcription factor NF- $\kappa$ B has been demonstrated in sarcoidosis (9, 45). NF- $\kappa$ B is normally inhibited by PPARG and modulates the expression of many pro-inflammatory genes implicated in sarcoidosis. Downstream dysreg-

ulation of the NF- $\kappa$ B pathway may contribute to even more altered amounts and activities of IL-6, interleukin-12, TNF- $\alpha$ , granulocyte/macrophage colony stimulating factor, intercellular adhesion molecule-1, macrophage chemotactic protein-1 and RANTES often found to be increased in patients with sarcoidosis (46-49).

The persistence of granulomatous inflammation in sarcoidosis might be due to reduced apoptosis of immune cells in granulomas (11, 50, 51). Various studies have suggested an important role of PPARG in regulating cell growth, differentiation, apoptosis and in pathogenesis of various tumors (28). Activation of PPARG with its specific agonists resulted in a marked increase of macrophage apoptosis even when low amounts of the agonist were used. It has been proposed that activation of PPARG may result in stimulation of TNF- $\alpha$ , IL-6, induced pro-apoptotic effect or in inhibition of TNF- $\alpha$ , IL6, induced anti-apoptotic pathway, the latter being NF- $\kappa$ B dependent (33).

Polymorphisms in the PPARG gene have been shown to regulate activity of the PPARG transcription factor *in vitro* (20, 52). The most commonly investigated polymorphism in the PPARG gene is the Pro12Ala polymorphism (53). The presence of Ala allele causes the protein product to decrease its binding affinity to its cognate promoter element and reduce its ability to transactivate its responsive promoters (20). The Pro12Ala polymorphism has been associated with type II diabetes, changes in insulin sensitivity, changes in insulin secretion and obesity (20, 54-60).

PPARGC1A is a transcriptional coactivator which enables PPARG to attain its full transcriptional activity (29). In previous studies, the PPARGC1A/ Gly482Ser polymorphism has also been associated with type II diabetes, obesity and insulin resistance (21, 61-66). The current results suggest that the presence of Ala(12) allele in PPARG and Ser(482) allele in PPARGC1A may predispose an individual to sarcoidosis. In this context, the data show a 145% increased risk of developing sarcoidosis in homozygous and heterozygous carriers of the Ala (12)/ PPARG allele and an 80% increased risk in homozygous and heterozygous carriers of the Ser(482)/PPARGC1A allele. As, to our knowledge, there have been no studies on the role of polymorphisms in PPARG and PPARGC1A genes in

etiopathogenesis of sarcoidosis, additional studies with a larger patient population and a broader ethnic background are needed to confirm these preliminary results.

The role of PPARG in the pathogenesis of sarcoidosis may have additional implications. PPARG activation after stimulation by prostaglandin-J2 or the thiazolidinedione rosiglitazone has been achieved with consequent anti-inflammatory effects (22-24). Such PPARG agonists could be used in the clinical treatment of sarcoidosis. Specific agonists of PPARG protein, such as rosiglitazone or pioglitazone are used in the treatment of diabetes (22, 23, 67). The immunosuppressive effect of these drugs may also attenuate granulomatous inflammation found in sarcoidosis. In conclusion, the results of the current study suggest a role of the PPARG and PPARGC1A genes and their polymorphisms in the genetic susceptibility and pathogenesis of sarcoidosis.

## REFERENCES

- Hance AJ. The role of mycobacteria in the pathogenesis of sarcoidosis. *Semin Respir Infect* 1998; 13: 197-205.
- McGrath DS, Goh N, Foley PJ, du Bois RM. Sarcoidosis: genes and microbes - soil or seed? *Sarcoidosis Vasc Diffuse Lung Dis* 2001; 18: 149-64.
- McGrath DS, Daniil Z, Foley P, et al. Epidemiology of familial sarcoidosis in the UK. *Thorax* 2000; 55: 751-4.
- Rybicki BA, Iannuzzi MC, Frederick MM, et al. Familial aggregation of sarcoidosis. A case-control etiologic study of sarcoidosis (ACCESS). *Am J Respir Crit Care Med* 2001; 164: 2085-91.
- Rybicki BA, Kirkey KL, Major M, et al. Familial risk ratio of sarcoidosis in African-American sibs and parents. *Am J Epidemiol* 2001; 153: 188-93.
- Luisetti M, Beretta A, Casali L. Genetic aspects in sarcoidosis. *Eur Respir J* 2000; 16: 768-80.
- Baughman RP, Lower EE, du Bois RM. Sarcoidosis. *Lancet* 2003; 361: 1111-8.
- Hristovski D, Peterlin B, Mitchell JA, Humphrey SM. Using literature-based discovery to identify disease candidate genes. *Int J Med Inform* 2005; 74 (2-4): 289-98.
- Culver DA, Barna BP, Raychaudhuri B, et al. Peroxisome proliferator-activated receptor gamma activity is deficient in alveolar macrophages in pulmonary sarcoidosis. *Am J Respir Cell Mol Biol* 2004; 30: 1-5.
- Rutherford RM, Staedtler F, Kehren J, et al. Functional genomics and prognosis in sarcoidosis - the critical role of antigen presentation. *Sarcoidosis Vasc Diffuse Lung Dis* 2004; 21: 10-8.
- Rutherford RM, Kehren J, Staedtler F, et al. Functional genomics in sarcoidosis - reduced or increased apoptosis? *Swiss Med Wkly* 2001; 131: 459-70.
- Minshall EM, Tsiopoulos A, Yasruel Z, et al. Cytokine mRNA gene expression in active and nonactive pulmonary sarcoidosis. *Eur Respir J* 1997; 10: 2034-9.
- Allen JT, Bloor CA, Knight RA, Spiteri MA. Expression of insulin-like growth factor binding proteins in bronchoalveolar lavage fluid of patients with pulmonary sarcoidosis. *Am J Respir Cell Mol Biol* 1998; 19: 250-8.
- Bloor CA, Knight RA, Kedia RK, Spiteri MA, Allen JT. Differential mRNA expression of insulin-like growth factor-1 splice variants in patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis. *Am J Respir Crit Care Med* 2001; 164: 265-72.
- Kinnula VL, Lehtonen S, Kaarteenaho-Wiik R, et al. Cell specific expression of peroxiredoxins in human lung and pulmonary sarcoidosis. *Thorax* 2002; 57: 157-64.
- Sabounchi-Schutt F, Astrom J, Hellman U, Eklund A, Grunewald J. Changes in bronchoalveolar lavage fluid proteins in sarcoidosis: a proteomics approach. *Eur Respir J* 2003; 21: 414-20.
- Koura T, Gon Y, Hashimoto S, Azuma A, et al. Expression of thioredoxin in granulomas of sarcoidosis: possible role in the development of T lymphocyte activation. *Thorax* 2000; 55: 755-61.
- Kim DS, Paik SH, Lim CM, et al. Value of ICAM-1 expression and soluble ICAM-1 level as a marker of activity in sarcoidosis. *Chest* 1999; 115: 1059-65.
- Schurmann M, Reichel P, Muller-Myshok B, Schlaak M, Muller-Quernheim J, Schwinger E. Results from a genome-wide search for predisposing genes in sarcoidosis. *Am J Respir Crit Care Med* 2001; 164 (5): 840-6.
- Deeb SS, Fajas L, Nemoto M, et al. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. *Nat Genet* 1998; 20: 284-7.
- Ek J, Andersen G, Urhammer SA, et al. Mutation analysis of peroxisome proliferator-activated receptor-gamma coactivator-1 (PGC-1) and relationships of identified amino acid polymorphisms to Type II diabetes mellitus. *Diabetologia* 2001; 44: 2220-6.
- Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. *Nature* 1998; 391: 79-82.
- Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. *Nature* 1998; 391: 82-6.
- Ricote M, Huang JT, Welch JS, Glass CK. The peroxisome proliferator-activated receptor (PPARgamma) as a regulator of monocyte/macrophage function. *J Leukoc Biol* 1999; 66: 733-9.
- Chinetti G, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. *Inflamm Res* 2000; 49:4 97-505.
- Delerive P, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors in inflammation control. *J Endocrinol* 2001; 169: 453-9.
- Daynes RA, Jones DC. Emerging roles of PPARs in inflammation and immunity. *Nat Rev Immunol* 2002; 2: 748-59.
- Standiford TJ, Keshamouni VG, Reddy RC. Peroxisome proliferator-activated receptor-gamma as a regulator of lung inflammation and repair. *Proc Am Thorac Soc* 2005; 2: 226-31.
- Puigserver P, Wu Z, Park CW, Graves R, Wright M, Spiegelman BM. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. *Cell* 1998; 92: 829-39.
- Choi YS, Hong JM, Lim S, Ko KS, Pak YK. Impaired coactivator activity of the Gly(482) variant of peroxisome proliferator-activated receptor gamma coactivator-1alpha (PGC-1alpha) on mitochondrial transcription factor A (Tfam) promoter. *Biochem Biophys Res Commun* 2006.
- Hunninghake GW, Costabel U, Ando M, et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association for Sarcoidosis and Other Granulomatous Disorders. *Sarcoidosis Vasc Diffuse Lung Dis* 1999; 16: 149-73.
- Bailey ST, Ghosh S. 'PPAR'ing ways with inflammation. *Nat Immunol* 2005; 6: 966-7.

33. Chinetti G, Griglio S, Antonucci M, et al. Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. *J Biol Chem* 1998; 273: 25573-80.
34. Elstner E, Muller C, Koshizuka K, et al. Ligands for peroxisome proliferator-activated receptor-gamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. *Proc Natl Acad Sci USA* 1998; 95: 8806-11.
35. Kawahito Y, Kondo M, Tsubouchi Y, et al. 15-deoxy-delta (12,14) PGJ(2) induces synovocyte apoptosis and suppresses adjuvant-induced arthritis in rats. *J Clin Invest* 2000; 106: 189-97.
36. Baughman RP, Strohofer SA, Buchsbaum J, Lower EE. Release of tumor necrosis factor by alveolar macrophages of patients with sarcoidosis. *J Lab Clin Med* 1990; 115: 36-42.
37. Bost TW, Riches DW, Schumacher B, et al. Alveolar macrophages from patients with beryllium disease and sarcoidosis express increased levels of mRNA for tumor necrosis factor-alpha and interleukin-6 but not interleukin-1 beta. *Am J Respir Cell Mol Biol* 1994; 10: 506-13.
38. Fireman E, Kraiem Z, Sade O, Greif J, Fireman Z. Induced sputum-retrieved matrix metalloproteinase 9 and tissue metalloproteinase inhibitor 1 in granulomatous diseases. *Clin Exp Immunol* 2002; 130: 331-7.
39. Gonzalez AA, Segura AM, Horiba K, et al. Matrix metalloproteinases and their tissue inhibitors in the lesions of cardiac and pulmonary sarcoidosis: an immunohistochemical study. *Hum Pathol* 2002; 33: 1158-64.
40. Henry MT, McMahon K, Mackarel AJ, et al. Matrix metalloproteinases and tissue inhibitor of metalloproteinase-1 in sarcoidosis and IPF. *Eur Respir J* 2002; 20: 1220-7.
41. Robinson BW, McLemore TL, Crystal RG. Gamma interferon is spontaneously released by alveolar macrophages and lung T lymphocytes in patients with pulmonary sarcoidosis. *J Clin Invest* 1985; 75: 1488-95.
42. Zissel G, Homolka J, Schlaak J, Schlaak M, Muller-Quernheim J. Anti-inflammatory cytokine release by alveolar macrophages in pulmonary sarcoidosis. *Am J Respir Crit Care Med* 1996; 154: 713-9.
43. Li M, Pascual G, Glass CK. Peroxisome proliferator-activated receptor gamma-dependent repression of the inducible nitric oxide synthase gene. *Mol Cell Biol* 2000; 20: 4699-707.
44. Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. *J Clin Invest* 2000; 106: 523-31.
45. Drent M, van den Berg R, Haenen GR, van den Berg H, Wouters EF, Bast A. NF-kappaB activation in sarcoidosis. *Sarcoidosis Vasc Diffuse Lung Dis* 2001; 18: 50-6.
46. Blackwell TS, Christman JW. The role of nuclear factor-kappa B in cytokine gene regulation. *Am J Respir Cell Mol Biol* 1997; 17: 3-9.
47. Itoh A, Yamaguchi E, Furuya K, et al. Correlation of GM-CSF mRNA in bronchoalveolar fluid with indices of clinical activity in sarcoidosis. *Thorax* 1993; 48: 1230-4.
48. Shigehara K, Shijubo N, Ohmichi M, et al. IL-12 and IL-18 are increased and stimulate IFN-gamma production in sarcoid lungs. *J Immunol* 2001; 166: 642-9.
49. Gurrieri C, Bortoli M, Brunetta E, Piazza F, Agostini C. Cytokines, chemokines and other biomolecular markers in sarcoidosis. *Sarcoidosis Vasc Diffuse Lung Dis* 2005; 22 Suppl 1: S9-14.
50. Kunitake R, Kuwano K, Miyazaki H, Hagimoto N, Nomoto Y, Hara N. Apoptosis in the course of granulomatous inflammation in pulmonary sarcoidosis. *Eur Respir J* 1999; 13: 1329-37.
51. Xaus J, Besalduch N, Comalada M, et al. High expression of p21 Waf1 in sarcoid granulomas: a putative role for long-lasting inflammation. *J Leukoc Biol* 2003; 74: 295-301.
52. Masugi J, Tamori Y, Mori H, Koike T, Kasuga M. Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-gamma 2 on thiazolidinedione-induced adipogenesis. *Biochem Biophys Res Commun* 2000; 268: 178-82.
53. Stumvoll M, Haring H. The peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism. *Diabetes* 2002; 51: 2341-7.
54. Altshuler D, Hirschhorn JN, Klannemark M, et al. The common PPARG gamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. *Nat Genet* 2000; 26: 76-80.
55. Clement K, Hercberg S, Passage B, et al. The Pro115Gln and Pro12Ala PPARG gamma gene mutations in obesity and type 2 diabetes. *Int J Obes Relat Metab Disord* 2000; 24: 391-3.
56. Douglas JA, Erdos MR, Watanabe RM, et al. The peroxisome proliferator-activated receptor-gamma2 Pro12Ala variant: association with type 2 diabetes and trait differences. *Diabetes* 2001; 50: 886-90.
57. Ek J, Andersen G, Urhammer SA, et al. Studies of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma2 (PPAR-gamma2) gene in relation to insulin sensitivity among glucose tolerant caucasians. *Diabetologia* 2001; 44: 1170-6.
58. Hara K, Okada T, Tobe K, et al. The Pro12Ala polymorphism in PPARG gamma2 may confer resistance to type 2 diabetes. *Biochem Biophys Res Commun* 2000; 271: 212-6.
59. Vaccaro O, Mancini FP, Ruffa G, Sabatino L, Colantuoni V, Riccardi G. Pro12Ala mutation in the peroxisome proliferator-activated receptor gamma2 (PPARG gamma2) and severe obesity: a case-control study. *Int J Obes Relat Metab Disord* 2000; 24: 1195-9.
60. Yen CJ, Beamer BA, Negri C, et al. Molecular scanning of the human peroxisome proliferator-activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: identification of a Pro12Ala PPARG gamma 2 missense mutation. *Biochem Biophys Res Commun* 1997; 241: 270-4.
61. Barroso I, Luan J, Sandhu MS, et al. Meta-analysis of the Gly482Ser variant in PPARGC1A in type 2 diabetes and related phenotypes. *Diabetologia* 2006; 49: 501-5.
62. Cheurfa N, Reis AF, Dubois-Laforgue D, Bellanne-Chantelot C, Timsit J, Velho G. The Gly482Ser polymorphism in the peroxisome proliferator-activated receptor-gamma coactivator-1 gene is associated with hypertension in type 2 diabetic men. *Diabetologia* 2004; 47: 1980-3.
63. Fanelli M, Filippi E, Sentinelli F, et al. The Gly482Ser missense mutation of the Peroxisome Proliferator-activated receptor gamma coactivator-1 alpha (PGC-1alpha) gene associates with reduced insulin sensitivity in normal and glucose-intolerant obese subjects. *Dis Markers* 2005; 21: 175-80.
64. Hara K, Tobe K, Okada T, et al. A genetic variation in the PGC-1 gene could confer insulin resistance and susceptibility to Type II diabetes. *Diabetologia* 2002; 45: 740-3.
65. Ridderstrale M, Johansson LE, Rastam L, Lindblad U. Increased risk of obesity associated with the variant allele of the PPARGC1A Gly482Ser polymorphism in physically inactive elderly men. *Diabetologia* 2006; 49: 496-500.
66. Vohl MC, Houde A, Lebel S, Hould FS, Marceau P. Effects of the peroxisome proliferator-activated receptor-gamma co-activator-1 Gly482Ser variant on features of the metabolic syndrome. *Mol Genet Metab* 2005; 86: 300-6.
67. Chawla A, Barak Y, Nagy L, Liao D, Tontonoz P, Evans RM. PPARG gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. *Nat Med* 2001; 7: 48-52.